DICHLOROTRICARBONYLRUTHENIUM (II) DIMER manufacturers
|
| | DICHLOROTRICARBONYLRUTHENIUM (II) DIMER Basic information |
| | DICHLOROTRICARBONYLRUTHENIUM (II) DIMER Chemical Properties |
| Melting point | 208°C (dec.) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | Soluble in DMSO | | form | crystal | | color | off-white | | Water Solubility | Insoluble in water | | InChI | 1S/6CO.4ClH.2Ru/c6*1-2;;;;;;/h;;;;;;4*1H;;/q;;;;;;;;;;2*+2/p-4 | | InChIKey | JYHHJVKGDCZCCL-UHFFFAOYSA-J | | SMILES | [C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].Cl[Ru]Cl.Cl[Ru]Cl |
| Hazard Codes | Xn | | Risk Statements | 20/21/22-36/37/38 | | Safety Statements | 26-37/39 | | RIDADR | UN3466 | | WGK Germany | 3 | | HazardClass | 6.1 | | PackingGroup | III | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral Eye Irrit. 2 Skin Irrit. 2 STOT SE 3 |
| | DICHLOROTRICARBONYLRUTHENIUM (II) DIMER Usage And Synthesis |
| Chemical Properties | Off-white to slightly yellow powder | | Uses | Tricarbonyldichlororuthenium(II) dimer is used to enhance the coagulation and attenuation of vulnerability to fibrinolysis, modify thrombus growth or disintegration, enhances fibrinogen as a substrate for thrombin, and regulation of ion transport by gasotransmitters. Also used for various pharmacological studies. It is used as a CO donor for reactive oxygen species mediated bacterial killing. | | reaction suitability | core: ruthenium reagent type: catalyst | | in vivo | Tricarbonyldichlororuthenium(II) dimer (1-10 mg/kg; oral gavage; single dose) has a protective effect in a rat model of gastric mucosal injury induced by ischemia-reperfusion[3]. | Animal Model: | Acute I/R gastric lesions treated male Wistar rats (250-300 g)[3] | | Dosage: | 1, 5 or 10 mg/kg | | Administration: | Oral gavage (i.g.); single dose | | Result: | Significantly decreased the area of I/R gastric damage and significantly increased GBF at doses of 1 or 5 mg/kg.
Significantly increased mRNA expression of HMOX-1 but not HMOX-2 in gastric mucosa and significantly increased blood concentration at dose of 5 mg/kg.
Significantly increased gastric mucosal PGE2 content at dose of 5 mg/kg.
Significantly decreased mRNA expression of iNOS but not eNOS in gastric mucosa at dose of 5 mg/kg.
Significantly decreased 8-hydroxyguanozine (8-OHG) concentration in gastric mucosa at dose of 5 mg/kg.
Decreased the expression of pro- and anti-inflammatory markers' mRNA and proteins at dose of 5 mg/kg. |
|
| | DICHLOROTRICARBONYLRUTHENIUM (II) DIMER Preparation Products And Raw materials |
|